Soleno Therapeutics/$SLNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
Ticker
$SLNO
Sector
Primary listing
Employees
182
Headquarters
Website
SLNO Metrics
BasicAdvanced
$1.7B
86.55
$0.39
-3.18
-
Price and volume
Market cap
$1.7B
Beta
-3.18
52-week high
$90.32
52-week low
$32.63
Average daily volume
1.6M
Financial strength
Current ratio
5.799
Quick ratio
5.438
Long term debt to equity
11.514
Total debt to equity
11.675
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
16.967
Gross margin (TTM)
98.58%
Net profit margin (TTM)
10.97%
Operating margin (TTM)
7.85%
Revenue per employee (TTM)
$1,050,000
Management effectiveness
Return on assets (TTM)
2.09%
Return on equity (TTM)
6.01%
Valuation
Price to earnings (TTM)
86.551
Price to revenue (TTM)
9.009
Price to book
3.92
Price to tangible book (TTM)
3.96
Price to free cash flow (TTM)
36.712
Free cash flow yield (TTM)
2.72%
Free cash flow per share (TTM)
0.919
Growth
Earnings per share change (TTM)
-108.90%
3-year earnings per share growth (CAGR)
-48.57%
10-year earnings per share growth (CAGR)
-43.91%
SLNO News
AllArticlesVideos
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Newsfile Corp·15 hours ago
ROSEN, A LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Newsfile Corp·2 days ago
ROSEN, A TOP RANKED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Newsfile Corp·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $1.7B as of March 16, 2026.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 86.55 as of March 16, 2026.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of March 16, 2026.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -3.18. This means that it has an inverse relation to market volatility.